Literature DB >> 18726883

Technical aspects of cytoreductive surgery.

Shigeki Kusamura1, Sarah T O'Dwyer, Dario Baratti, Rami Younan, Marcello Deraco.   

Abstract

At the Fifth International Workshop on Peritoneal Surface Malignancy, in Milan, the consensus on technical aspects of cytoreductive surgery (CRS) for peritoneal surface malignancy was obtained through the Delphi process. Five conflicting points were discussed: radicality of the peritonectomy procedure, cytoreduction of neoplastic nodules <2.5 mm, the timing of bowel anastomoses in relation to hyperthermic intraperitoneal chemotherapy (HIPEC) and indications of protective ostomies. According to the panel of experts a partial parietal peritonectomy restricted to the macroscopically involved regions could be indicated in all listed clinical conditions with the exception of peritoneal mesothelioma. No expert was of the opinion that a radical parietal peritonectomy is advisable irrespective of the disease being treated. All the experts agreed that electrovaporization of small (<2.5 mm) non-infiltrating metastatic nodules in the mesentery would be appropriate, even if theoretically the HIPEC affords microscopic cytoreduction. The panel also agreed that in the closed technique for HIPEC administration the intestinal anastomoses should be fashioned after completion of the perfusion. Finally when considering the place for protective ostomies the experts voted for a flexible approach allowing the surgeon to exercise discretion for individual patients.

Entities:  

Mesh:

Year:  2008        PMID: 18726883     DOI: 10.1002/jso.21058

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

Review 1.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignant disease.

Authors:  Wenceslao Vásquez Jiménez; Luis González Bayón; José Luis García-Sabrido; Santiago González Moreno
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  Bowel Anastomosis After or Before HIPEC: A Comparative Study in Patients Undergoing CRS+HIPEC for Peritoneal Surface Malignancy.

Authors:  S P Somashekhar; Kumar C Rohit; Yethadka Ramya; Shabber S Zaveri; Vijay Ahuja; Arun Kumar Namachivayam; K R Ashwin
Journal:  Ann Surg Oncol       Date:  2021-08-30       Impact factor: 5.344

4.  Ovarian preservation with subcutaneous transposition in the setting of cytoreductive surgery.

Authors:  Winson Jianhong Tan; Jingjin Jung; Claramae Shulyn Chia; Melissa Ching Ching Teo; Han Chong Toh; Khee Chee Soo
Journal:  Int J Surg Case Rep       Date:  2013-01-17

Review 5.  Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.

Authors:  Seung Yoon Yang; Jae Hyun Kang; Ho Seung Kim; Yoon Dae Han; Byung Soh Min; Kang Young Lee
Journal:  J Gastrointest Oncol       Date:  2019-12

6.  Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study.

Authors:  Antonio Macrì; Fabio Accarpio; Vincenzo Arcoraci; Francesco Casella; Franco De Cian; Pierandrea De Iaco; Elena Orsenigo; Franco Roviello; Giovanni Scambia; Edoardo Saladino; Marica Galati
Journal:  Pleura Peritoneum       Date:  2020-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.